As clinicians increasingly make use of amyloid PET, they need to know where to draw the line between amyloid-negative and -positive scans. In the July 13 JAMA, scientists led by Ganna Blazhenets and ...

Scientists offer new clues as to how overzealous neuronal firing may fuel synaptic loss in early Alzheimer's. In Science July 9, scientists led by Soyon Hong at University College London report that ...

In the quest to understand how APOE4 heightens the risk of Alzheimer’s disease, scientists are drilling down to nuances such as how the variant acts in women versus men, and how it affects cell types.

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

The notion that lithium might treat Alzheimer’s was revived last year when scientists reported that the brains of people and mice with amyloid pathology are deficient in the metal ion, and that the ...

Even though there were no big revelations from immunotherapy trials at this year’s International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to April 1 in Gothenburg, Sweden, new ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

The MAPT haplotypes H1 and H2 are defined by a large inversion polymorphism on chromosome 17. The HI haplotype has been consistently linked to risk for several neurodegenerative diseases, particularly ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

Alzheimer’s researchers have long wished for better mouse models. That is now coming true. Scientists at the Jackson Laboratory in Bar Harbor, Maine, are cranking out numerous lines that express ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...